IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

D'AMBROSIO, ROBERTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.101
NA - Nord America 2.455
AS - Asia 1.333
SA - Sud America 44
AF - Africa 25
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 7
Totale 7.985
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.337
GB - Regno Unito 1.865
DE - Germania 719
CN - Cina 633
SE - Svezia 426
IT - Italia 418
SG - Singapore 234
IN - India 151
RU - Federazione Russa 128
IE - Irlanda 118
CA - Canada 100
UA - Ucraina 98
FR - Francia 96
KR - Corea 71
TR - Turchia 70
DK - Danimarca 62
FI - Finlandia 61
HK - Hong Kong 49
EU - Europa 47
ID - Indonesia 32
NL - Olanda 30
BE - Belgio 24
JP - Giappone 24
AU - Australia 18
TW - Taiwan 18
CO - Colombia 17
MX - Messico 15
BR - Brasile 13
EG - Egitto 13
ES - Italia 13
GR - Grecia 11
CH - Svizzera 10
CL - Cile 10
UG - Uganda 9
IL - Israele 8
UZ - Uzbekistan 8
VN - Vietnam 7
IR - Iran 6
TH - Thailandia 6
MM - Myanmar 5
PK - Pakistan 4
PT - Portogallo 4
RO - Romania 4
BG - Bulgaria 3
MY - Malesia 3
PL - Polonia 3
AT - Austria 2
CR - Costa Rica 2
IS - Islanda 2
NZ - Nuova Zelanda 2
PE - Perù 2
SA - Arabia Saudita 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
JE - Jersey 1
KZ - Kazakistan 1
LT - Lituania 1
NO - Norvegia 1
PA - Panama 1
PY - Paraguay 1
TM - Turkmenistan 1
VE - Venezuela 1
Totale 8.026
Salva come PNG Salva come JPEG
Città #
Southend 1.765
Chandler 330
Milan 190
Seattle 172
Singapore 159
Princeton 138
Wilmington 134
Beijing 123
Hanover 122
Fairfield 118
Dublin 117
Ashburn 114
Ann Arbor 98
Dearborn 97
Woodbridge 81
Houston 80
Toronto 75
Nanjing 74
Frankfurt am Main 71
Jacksonville 56
Des Moines 55
Mountain View 52
Cambridge 50
Andover 46
Redmond 45
Bengaluru 44
Boardman 38
Hong Kong 33
Jinan 29
New York 28
Guangzhou 27
Santa Clara 27
Phoenix 26
Serra 26
Shenyang 26
Berlin 25
Shanghai 25
Kent 24
Brussels 23
Hebei 23
Sakarya 23
Piscataway 22
Saint Petersburg 20
San Diego 20
Somerville 18
Bogotá 17
Jakarta 17
Jiaxing 17
Changsha 15
Helsinki 15
Redwood City 15
Zhengzhou 14
Hangzhou 13
Ottawa 13
Tianjin 12
Turin 12
Bitonto 11
Grafing 11
Margão 11
Mumbai 11
Taiyuan 11
Athens 10
Auburn Hills 10
Kampala 9
Nanchang 9
San Antonio 9
Cairo 8
Central District 8
Eitensheim 8
Falls Church 8
Kunming 8
Munich 8
Montreal 7
Rho 7
Sunnyvale 7
Bühl 6
Florence 6
Fremont 6
Fuzhou 6
Haikou 6
Los Angeles 6
Seoul 6
Taichung 6
Taizhou 6
Bangkok 5
Dong Ket 5
Istanbul 5
Ixtlán del Río 5
Pune 5
Silver Spring 5
Tokyo 5
Vadodara 5
Verona 5
Wuhan 5
Yangon 5
Bari 4
Cinisello Balsamo 4
Guadalajara 4
Hefei 4
Kaohsiung City 4
Totale 5.349
Salva come PNG Salva come JPEG
Nome #
Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs 299
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 262
Prevalence of psychiatric disorders during PEG – Interferon and Ribavirin therapy in patients with chronic hepatitis HCV-correlated 260
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 202
The international autoimmune hepatitis group scoring system in patients with chronic hepatitis C and serum autoantibodies undergoing interferon/ribavirin therapy : a prospective validation study 201
Hepatitis C virus deletion mutants are found in individuals chronically infected with genotype 1 hepatitis c virus in association with age, high viral load and liver inflammatory activity 191
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 180
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 179
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving telaprevir 170
The natural history of portal hypertension in patients with HCV related compensated cirrhosis undergoing interferon ribavirin therapy 166
Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis 161
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy 160
A morphometric and immunohistochemical study to assess the benefit of an svr in hcv cirrhotic patients 153
The influence of liver fibrosis on the outcome of pegylated interferon and ribavirin anti-hac therapy : a sub-analysis of the mist study 150
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 150
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C 148
The relationship between liver histology and thyroid function tests in patients with nonalcoholic fatty liver disease (NAFLD) 148
Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients : a single-centre study 146
Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients 146
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 145
Standard and pegylated interferon alfa-2b plus ribavirin as initial treatment for HCV genotype 2 chronic hepatitis : analysis of a large single center cohort 141
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 141
A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis : the interferon-inducible gene IFI16 140
A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms 138
The diagnostic accuracy of fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with an SVR 137
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4 136
Interferoni pegilati nel trattamento dei pazienti con epatite cronica HCV : esperienze a confronti 135
The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype 134
Low rates of sustained virological response to interferon and ribavirin therapy in genotype 3 infected patients with compensated cirrhosis 133
Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3α hepatitis C virus infection 132
Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy 131
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 130
Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B 128
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 126
Randomized Study of Peginterferon-alpha2a Plus Ribavirin vs Peginterferon-alpha2b Plus Ribavirin in Chronic Hepatitis C 125
Lack of alanine aminotransferase normalization in patients with an anti-hcv virological response during pegylated interferon and ribavirin therapy : a sub-analysis of the mist study 122
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis 120
HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin 117
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy 117
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 116
Impact of HCV and Direct Acting Antivirals on Kidney Recipients: a retrospective study 116
Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis 111
Hepatocellular carcinoma in patients with compensated HCV-related cirrhosis responding to interferon : A 5-year follow-up study 108
Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression 100
Transient elastography to assess liver fibrosis in patients with sickle cell disease 96
The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response 96
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 93
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: Case study 85
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review) 83
Treatment of experienced and naïve patients with hepatitis C : focus on telaprevir 82
Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker Therapy 82
Treatment of patients with HCV related cirrhosis : many rewards with very few risks 80
Pegylated interferons and ribavirin therapy for the treatment of chronic hepatitis C in thalassaemia major patients : preliminary results 77
Safety of direct antiviral agents in real life 75
Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients 71
Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19 71
Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis 70
Treating hepatitis C in patients with hemoglobinopathies 64
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 64
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study 64
Editorial : good news to patients with thalassaemia €”HCV clearance made easy with direct-acting antivirals 61
A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C 60
Proteomics to predict hepatitis C therapy outcome : where do we stand? 58
Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis 56
Treatment of non-alcoholic steatosis : Preclinical study of a new nutraceutical multitarget formulation 54
Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy 52
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores 49
Rare ATG7 genetic variants predispose patients to severe fatty liver disease 46
Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: A case series 33
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 32
Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease 31
Editorial: the role for PIVKA-II measurement after HCV elimination by direct-acting antivirals in terms of prediction of hepatocellular carcinoma—authors' reply 29
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 27
Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction 19
null 19
Is it time to refine HCC surveillance strategies in HCV cured patients? 16
null 3
Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease 2
null 1
Totale 8.552
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.080
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.080
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020851 0 0 0 124 53 132 101 65 180 140 32 24
2020/20211.038 72 71 74 58 76 51 58 112 99 54 198 115
2021/20221.121 84 61 34 86 129 97 95 74 125 105 66 165
2022/20231.180 142 143 111 138 116 207 17 77 127 23 59 20
2023/2024809 47 66 30 54 222 65 34 39 49 36 70 97
2024/2025384 67 235 34 48 0 0 0 0 0 0 0 0
Totale 8.552